To disseminate the first ever guidelines for Management of Polycystic Ovary Syndrome (PCOS) in India at the PCOS India Summit 2015 held in Delhi and Kolkata, Bayer Zydus Pharma supported the Indian Fertility Society (IFS) on the occasion of Women’s Day. This was also marked by a multi-specialty interactive scientific symposium bringing together leading medical practitioners from the field of gynecology, dermatology, endocrinology, pediatrics and radiology.

These guidelines aim at simplifying patient management, through involvement of various medical specialties suggesting symptom- and age-based approaches towards optimal treatment of patients.
Polycystic Ovary Syndrome (PCOS) is a complex metabolic, endocrine and reproductive disorder that results in overproduction of male hormones, and is associated with insulin resistance (IR).

Bayer Zydus Pharma intends to further disseminate these guidelines to approximately 5000 doctors across India. “We at Bayer are committed to improve the health and well-being of our patients. We intend to take these guidelines further by way of educational programs for doctors across cities in India. This initiative is in line with our mission at Bayer – Science for a Better Life” says Angel- Michael Evangelista, managing director, Bayer Zydus Pharma

Dr Sonia Malik, president of Indian Fertility Society and Principal author of the Guidelines of Management of PCOS in India says, “Given higher risk of PCOS in Indian women and the heterogeneous and complex nature of the disease, there was a need for a sustained, multi-pronged, multi-disciplinary approach for the optimal management of PCOS. These guidelines are a culmination of the hard work and diligent efforts on part of a multidisciplinary panel of doctors from various parts of India.”

The recently developed guidelines for PCOS management are the first- of- its- kind in India. These guidelines engage medical practioners from multiple-disciplines and spell out an algorithmic approach to treating PCOS.

Dr. Malik at the summit encouraged the physicians in India to optimize PCOS management by adhering to these guidelines.

The common symptoms of PCOS range from menstrual disorders, infertility, acne and increased facial hair to metabolic syndrome (MS). The prevalence rate of PCOS in India is as high as 22% which is much higher as compared to that in developed countries where it is approximately 5- 10%.

Bayer Zydus Pharma, the joint venture company of Bayer HealthCare and Zydus Cadila, is backed by strong research and development and a novel therapeutic approach. Focused on patients' healthcare needs in India, Bayer Zydus Pharma offers innovative healthcare solutions in the area of women's healthcare, general medicine, specialty medicine and diagnostic imaging.